Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/99366
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis |
Author: | Ahmadian, A. Brogan, A. Berman, J. Sverdlov, A. Mercier, G. Mazzini, M. Govender, P. Ruberg, F. Miller, E. |
Citation: | Journal of Nuclear Cardiology, 2014; 21(5):925-939 |
Publisher: | Springer |
Issue Date: | 2014 |
ISSN: | 1071-3581 1532-6551 |
Statement of Responsibility: | Azadeh Ahmadian, Ashley Brogan, Jeffrey Berman, Aaron L. Sverdlov, Gustavo Mercier, Michael Mazzini, Praveen Govender, Frederick L. Ruberg, and Edward J. Mille |
Abstract: | Background: FDG PET/CT with myocardial perfusion imaging is a useful method for evaluating cardiac sarcoidosis (CS), but interpretation is not standardized. We developed a method for quantification of cardiac FDG PET/CT and evaluated its relationship to conventional interpretation, perfusion defects, clinical events, and immunosuppressive treatment. Methods and Results: FDG PET/CT with MPI studies performed for CS (n = 38) were retrospectively compared to negative control studies acquired for oncologic indications (n = 10). Quantitative measures of FDG volume-intensity (Cardiac Metabolic Activity, CMA) was performed using standardized uptake values (SUVs). CMA (477.7 ± 909 vs 0.55 ± 2.1 vs 0.3 ± 0.3 g glucose, P = .02) was significantly greater in visually FDG-positive studies compared to visually negative and oncologic negative studies. Among patients with CS, CMA was greater in studies with an EF < 50% (760.3 ± 1,148 vs 87.4 ± 161 g glucose, P = .03) and preceding an adverse clinical event (1,095 ± 1,253 vs 73 ± 144 g glucose, P = .006). CMA was the only independent predictor of events by multivariate analysis. In patients with repeat examinations (n 5 7), CMA decreased with prednisone treatment in 5 of 6 patients. Conclusions: Quantification of FDG uptake in CS correlates with lower EFs, clinical events, and immunosuppression treatment. |
Keywords: | Metabolism: PET; PET/CT imaging; fluorodeoxyglucose (FDG) |
Rights: | Copyright © 2014 American Society of Nuclear Cardiology. |
DOI: | 10.1007/s12350-014-9901-9 |
Published version: | http://dx.doi.org/10.1007/s12350-014-9901-9 |
Appears in Collections: | Aurora harvest 3 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.